Golden Legand Ls (509024)

Score breakdown: P/E: 3/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Top-line growth of 2,968.45% suggests the company is now generating meaningful business volume.
• Trailing P/E of 2.63 appears optically cheap if the reported earnings are to be believed.
• Latest quarter revenue of ₹57 Cr is far larger than the ₹16 Cr market cap, implying a very low price-to-sales ratio.
• Reported ROE of 70.01% reflects high returns on a very small book value, which could attract attention if sustained.

Concerns

• Latest quarter net loss of ₹6 Cr on ₹57 Cr sales means the reported growth is not yet translating to profits.
• ROCE of -11.71% and profit growth of -249.07% point to value destruction, not recovery.
• P/B of 10.35 is very expensive; book value of ₹10.61 offers little downside support at a price of ₹109.80.
• Piotroski F-Score of 3/9, zero dividend, and undisclosed promoter holding make financial health and governance unclear.

AI Analysis

I start with a simple rule: I'd rather buy a wonderful company at a fair price than a poor company at a wonderful price. Golden Legand Ls fails that test. The surface numbers look like a statistical bargain: P/E of 2.63 and sales growth of 2,968.45%. But Graham taught me to look beneath the surface. A non-banking financial company with a negative ROCE of -11.71% is not earning a return on invested capital. The reported ROE of 70.01% is merely a function of a very thin equity base—book value of only ₹10.61 per share—not a sign of durable profitability. The latest quarter tells the real story: sales of ₹57 Cr but a net loss of ₹6 Cr. That means the new business is unprofitable. Profit growth is -249.07%, so the bottom line is deteriorating. The Piotroski F-Score of 3/9 reinforces my concern about weak financial health. On top of all this, I would be paying ₹109.80 per share, or 10.35 times book value, for a microcap with a ₹16 Cr market capitalisation. That is no margin of safety by Graham’s standard. There is no dividend to reward patient capital, promoter holding is not disclosed, and the 52-week range of ₹7.50 to ₹109.80 looks like a speculative punt, not a business trajectory. Perhaps the company is attempting a turnaround with a massive revenue jump, but a value investor should not pay up before profitability is proven. This is not a predictable compounder; it is a lottery ticket priced as if it deserves a growth multiple. I cannot value a business whose earnings quality is this poor and whose financial-health score is 3 out of 9. As Buffett says, 'It’s better to wait for the fat pitch'—this is not that pitch. I would pass.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer